参考文献
［1］ Ballinger WF，Lacy PE.Transplantation of intact pancreatic islets in rats［J］.Surgery，1972，72（2）：175-186.
［2］ Shapiro AM，Lakey JR，Ryan EA，et al.Islet transplantation in seven patients with type 1diabetes mellitus using aglucocorticoid-free immunosuppressive regimen［J］.N Engl J Med，2000，343（4）：230-238.
［3］ Shapiro AM，Ricordi C，Hering BJ，et al.International trial of the Edmonton protocol for islet transplantation［J］.N Engl J Med，2006，355（13）：1318-1330.
［4］ Brennan DC，Kopetskie HA，Sayre PH，et al.Long-term follow-up of the Edmonton protocol of islet transplantation in the United States［J］.Am J Transplant，2016，16（2）：509-517.
［5］ Bottino R，Lehmann R.Improved human islet isolation using a new enzyme blend，liberase［J］.Diabetes，1997，46（7）：1120-1123.
［6］ O'Donnell L.Risk of bovine spongiform encephalopathy（BSE）in collagenase enzymes［J］.ISCT Telegraft Newsletter，2006.
［7］ Sabek OM，Cowan P，Fraga DW，et al.The effect of isolation methods and the use of different enzymes on islet yield and in vivo function［J］.Cell Transplant，2008，17（7）：785-793.
［8］ O'Donnell L，Kin T，Imes S，et al.Comparison of human islet isolation outcomes using a new mammalian tissue-free enzyme versus collagenase NB-1［J］.Transplantation，2010，90（3）：255-266.
［9］ Calballero-Corbalan J，Brandhorst H，Asif S，et al.Mammalian tissue-free liberase：a new GMPgraded enzyme blend for human islet isolation［J］.Transplantation，2010，90（3）：332-341.
［10］ Taylor GD，Kirkland T，Lakey J，et al.Bacteremia due to transplantation of contaminated cryopreserved pancreatic islets［J］.Cell Transplant.1994，3（1）：103-106.
［11］ Ricordi C，Gray DW，Hering BJ，et al.Islet isolation assessment in man and large animals［J］.Acta Diabetol Lat，1990，27（3）：185-195.
［12］ Owen RJ，Ryan EA，O'Kelly K，et al.Percutaneous transhepatic pancreatic islet cell transplantation in type 1diabetes mellitus：radiologic aspects［J］.Radiology，2003，229（1）：165-170.
［13］ Hering BJ，Kandaswamy R，Ansite JD，et al.Single-donor，marginal-dose islet transplantation in patients with type 1diabetes［J］.JAMA，2005，293（7）：830-835.
［14］ Hering BJ，Kandaswamy R，Harmon JV，et al.Transplantation of cultured islets from two-layer preserved pancreases in type 1diabetes with anti-CD3antibody［J］.Am J Transplant，2004，4（3）：390-401.
［15］ Kaplan B，Schold J，Srinivas T，et al.Effect of sirolimus withdrawal in patients with deteriorating renal function［J］.Am J Transplant，2004，4（10）：1709-1712.
［16］ Gruessner RW，Burke GW，Stratta R，et al.A multicenter analysis of the first experience with FK506for induction and rescue therapy after pancreas transplantation［J］.Transplatation，1996，61（2）：261-273.
［17］ Zhang Y，Shen W，Hua J，et al.Pancreatic islet-like clusters from bone marrow mesenchymal stem cells of human first-trimester abortus can cure streptozocin-induced mouse diabetes［J］.Rejuven Res，2010，13（6）：695-706.
［18］ Bhandari DR，Seo KW，Sun B，et al.The simplest method for in vitro beta-cell production from human adult stem cells［J］.Differentiation，2011，82（3）：144-152.
［19］ Busik JV，Mohr S，Grant MB.Hyperglycemia-induced reactive oxygen species toxicity to endothelial cells is dependent on paracrine mediators［J］.Diabetes，2008，57（7）：1952-1965.
［20］ 王维，等.采用Edmonton免疫抑制方案的成人胰岛移植治疗1型糖尿病八例［J］.中华器官移植杂志，2003，37（11）：1029-1035.
［21］ 蔺武军，毕玉田，陈东风.胰腺神经内分泌肿瘤的诊治进展［J］.胃肠病学和肝病学杂志，2017（2）：234-238.
［22］ 中华医学会外科学分会胰腺外科学组.胰腺神经内分泌肿瘤治疗指南（2014）［J］.中华肝胆外科杂志，2014，20（12）：841-844.
［23］ McKillop GM，et al.Vibration perception thresholds in 279diabetic patients［J］.Scott Med J，1988，33（5）：334-335.
［24］ Rand LI.Diabetic retinopathy：can we modify its course？［J］.American Journal of Medicine，1991，90（2a）：66-69.
［25］ Mackay IR.Dependent diabetes mellitus［J］.J Autoimmun，1996，9（6）：705-711.
［26］ Aiello LP，Cahill MT，Wong JS.Systemic considerations in the management of diabetic retinopathy［J］.Am J Ophthalmol，2001，132（5）：760-776.
［27］ Al-Daghri NM，Alkharfy KM，Al-Othman A，et al.Vitamin D supplementation as an adjuvant therapy for patients with T2DM：an 18-month prospective interventional study［J］.Cardiovasc Diabetol，2012，11：85.
［28］ El-Naggar N，Almansari A，Khudada K，et al.The A1chieve study—an observational noninterventional study of patients with type 2diabetes mellitus initiating or switched to insulin analogue therapy：subgroup analysis of the Gulf population［J］.International Journal of Clinical Practice，2013，67（2）：128-138.(https://www.daowen.com)
［29］ Ferrari GL，Marques JLB，Gandhi RA，et al.An approach to the assessment of diabetic neuropathy based on dynamic pupillometry［J］.Conf Proc IEEE Eng Med Biol Soc，2007，207：557-560.
［30］ Ferrari GL，Marques JLB，Gandhi RA，et al.Using dynamic pupillometry as a simple screening tool to detect autonomic neuropathy in patients with diabetes：apilot study［J］.Biomed Eng Online，2010，9：26.
［31］ Freemantle N，Balkau B，Danchin N，et al.Factors influencing initial choice of insulin therapy in a large international non-interventional study of people with type 2diabetes［J］.Diabetes Obes Metab，2012，14（10）：901-909.
［32］ Gallwitz B，Kusterer K，Hildemann S，et al.Type 2diabetes and its therapy in clinical practice—results from the standardised non-interventional registry SIRTA［J］.International Journal of Clinical Practice，2014，68（12）：1442-1453.
［33］ Home P，Naggar NE，Khamseh M，et al.An observational non-interventional study of people with diabetes beginning or changed to insulin analogue therapy in non-Western countries：the alchieve study［J］.Diabetes Res Clin Pract，2011，94（3）：352-363.
［34］ Lafayetted RA，Mccall B，Li N，et al.Incidence and relevance of proteinuria in bevacizumab-treated patients：pooled analysis from randomized controlled trials［J］.Am J Nephrol，2014，40（1）：75-83.
［35］ Lapcevic M，Vukovic'M，Dimitrijevic'I，et al.The effect of medicamentous and non-medicamentous therapy on lowering risk factors for cardiovascular and cerebrovascular episodes in an interventional study［J］.Srp Arh Celok Lek，2007，135（9-10）：554-561.
［36］ Lin Y，Yang X，Chen Z，et al.Demonstration of the dorsal pancreatic artery by CTA to facilitate superselective arterial infusion of stem cells into the pancreas［J］.European Journal of Radiology，2012，81（3）：461-465.
［37］ Neergaard-Petersen S，Hvas AM，Kristensen S，et al.Platelets and antiplatelet therapy in patients with coronary artery disease and diabetes［J］.Seminars in Thrombosis and Hemostasis，2016，42（3）：234-241.
［38］ Masato Odawara，Takashi Kadowaki，Yusuke Naito.Effectiveness and safety of basal supported oral therapy with insulin glargine，in Japanese insulin-naive，type 2diabetes patients，with or without microvascular complications：subanalysis of the observational，non-interventional，24-week follow-up Add-on Lantus（R）to Oral Hypoglycemic Agents（ALOHA）study［J］.J Diabetes Complications，2015，29（1）：127-133.
［39］ Perugini RA，Malkani S.Malkani Remission of type 2diabetes mellitus following bariatric surgery：review of mechanisms and presentation of the concept of reversibility［J］.Curr Opin Endocrinol Diabetes Obes，2011，18（2）：119-128.
［40］ Ruige JB.Does low testosterone affect adaptive properties of adipose tissue in obese men？［J］.Arch Physiol Biochem，2011，117（1）：18-22.
［41］ Segal D，Tupy D，Distiller LA.The Biosulin equivalence in standard therapy（BEST）study—a multicentre，open-label，non-randomised，interventional，observational study in subjects using Biosulin 30／70for the treatment of insulin-dependent type 1and type 2diabetes mellitus［J］.S Afr Med J，2013，103（7）：458-460.
［42］ Sun NF，Tian AL，Tian YL，et al.The interventional therapy for diabetic peripheral artery disease［J］.Bmc Surgery，2013，13：32.
［43］ Kindmark H，Sundin A，Granberg D，et al.Endocrine pancreatic tumors with glucagon hypersecretion：a retrospective study of 23cases during 20years［J］.Med Oncol，2007，24（3）：330-337.
［44］ Xiao L，Huang DS，Tong JJ，et al.Efficacy of endoluminal interventional therapy in diabetic peripheral arterial occlusive disease：a retrospective trial［J］.Cardiovasc Diabetol，2012，11：17.
［45］ Du S，Ni J，Weng L，et al.Aggressive locoregional treatment improves the outcome of liver metastases from grade 3gastroenteropancreatic neuroendocrine tumors［J］.Medicine（Baltimore），2015，94（34）：e1429.
［46］ Dumlu EG，KarakoçD，Özdemir A，et al.Nonfunctional pancreatic neuroendocrine tumors：advances in diagnosis，management，and controversies［J］.International Surgery，2015，100（6）：1089-1097.
［47］ Gall TM，Thompson Z，Dinneen EP，et al.Surgical techniques for improving outcomes in pancreatic ductal adenocarcinoma［J］.Expert Rev Gastroenterol Hepatol，2014，8（3）：241-246.
［48］ Go VLW，Srihari P，Kamerman BLA.Nutrition and gastroenteropancreatic neuroendocrine tumors［J］.Endocrinol Metab Clin North Am，2010，39（4）：827-837.
［49］ Gurusamy KS，Pamecha V，Sharma D，et al.Palliative cytoreductive surgery versus other palliative treatments in patients with unresectable liver metastases from gastro-entero-pancreatic neuroendocrine tumours［J］.Cochrane Database Syst Rev，2009（1）：Cd007118.
［50］ Kumar S.Islet amyloid-induced cell death and bilayer integrity loss share a molecular origin targetable with oligopyridylamide-based alpha-helical mimetics［J］.Chem Biol，2015，22（3）：369-378.
［51］ Modlin IM，Oberg K，Chung DC，et al.Gastroenteropancreatic neuroendocrine tumours［J］.Lancet Oncol，2008，9（1）：61-72.
［52］ O'Grady HL，Conlon KC.Conlon Pancreatic neuroendocrine tumours［J］.Eur J Surg Oncol，2008，34（3）：324-332.
［53］ Okabayashi T，Shima Y，Sumiyoshi T，et al.Diagnosis and management of insulinoma［J］.World J Gastroenterol，2013，19（6）：829-837.
［54］ Nomura N，Fujii T，Kanazumi N，et al.Nonfunctioning neuroendocrine pancreatic tumors：our experience and management［J］.J Hepatobiliary Pancreat Surg，2009，16（5）：639-647.
［55］ Okada T，Nishimura T，Nakamura M，et al.Non-functional pancreatic endocrine carcinoma with multiple liver metastases—a case report［J］.Gan To Kagaku Ryoho，2010，37（12）：2370-2372.
［56］ Dumlu EG，KarakoçD，Özdemir A，et al.Nonfunctional pancreatic neuroendocrine tumors：advances in diagnosis，management，and controversies［J］.International Surgery，2015，100（6）：1089-1097.